<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01964989</url>
  </required_header>
  <id_info>
    <org_study_id>V118_05</org_study_id>
    <secondary_id>2012-000218-12</secondary_id>
    <nct_id>NCT01964989</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.</brief_title>
  <official_title>A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to &lt; 72 Months of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus
      Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to &lt;72 Months
      of Age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RT-PCR-confirmed influenza cases in all subjects</measure>
    <time_frame>Weekly from Day 1 up to 180 days after the last vaccination or until the end of the influenza season, whichever is longer</time_frame>
    <description>The relative efficacy of aQIV compared to comparator vaccine as determined by RT-PCR-confirmed influenza</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with solicited AEs</measure>
    <time_frame>For 7 days following each vaccination</time_frame>
    <description>To evaluate safety and tolerability of each study vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with all unsolicited AEs</measure>
    <time_frame>vaccine-naïve subjects: Day 1 to Day 50; vaccine non-naïve subjects: Day 1 to 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with SAEs, AEs leading to withdrawal from the study or study vaccination, new onset of chronic disease, Adverse Event of Special Interest (AESI) and all medications associated</measure>
    <time_frame>12 months after last vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hazard ratios calculated: Occurrence of RT-PCR and culture-confirmed influenza cases in all subjects</measure>
    <time_frame>occurring at ≥ 21 days and ≤ 180 days after the last vaccination or until the end of the influenza season, whichever is longer,</time_frame>
    <description>Efficacy:
The relative efficacy of aQIV compared to comparator as determined by the proportion of subjects with culture-confirmed influenza The relative efficacy of aQIV compared to comparator as determined by RT-PCR-confirmed and culture-confirmed influenza in age subgroups, in children at risk of influenza, and in children depending on previous vaccination status The early relative efficacy of aQIV compared to comparator as determined by RT-PCR-confirmed influenza</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hazard ratios calculated: Early occurrence of RT-PCR-confirmed influenza cases in all subjects</measure>
    <time_frame>on first-occurrence of RT-PCR-confirmed influenza cases</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean HI titer (GMT)</measure>
    <time_frame>vaccine naïve subjects: on Day 1, Day 29, Day 50 and Day 209, vaccine non-naïve subjects: on Day 1, Day 22 and Day 181</time_frame>
    <description>Immunogenicity:
To compare antibody responses between aQIV and comparator (including assessment of non-inferiority and superiority)
The endpoints for immunogenicity measured in aQIV and comparator as determined by HI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean ratio (GMR)</measure>
    <time_frame>vaccine naïve subjects on Day 29/Day 1, Day 50/Day 1 and Day 209/Day 1, vaccine non-naïve: Day 22/Day 1 and Day 181/Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of vaccine naïve and non-naïve subjects achieving seroconversion</measure>
    <time_frame>vaccine naïve subjects: on Day 29 and Day 50, vaccine non-naïve subjects: on Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with HI titer ≥ 1:40</measure>
    <time_frame>vaccine naïve subjects on Day 29, Day 50 and Day 209, vaccine non-naïve: Day 22 and Day 181</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with higher HI titer thresholds</measure>
    <time_frame>vaccine naïve subjects on Day 29, Day 50 and Day 209, vaccine non-naïve: Day 22 and Day 181</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with all unsolicited AEs</measure>
    <time_frame>from Day 1 to Day 50, vaccine non-naïve subjects from Day 1 to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with SAEs, AEs leading to withdrawal from the study or study vaccination, New Onset of Chronic Disease (NOCD), Adverse Events of Special Interest(AESI) and all medications associated</measure>
    <time_frame>12 months after last vaccination</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of subjects with a medical visit for respiratory illness associated with RT-PCR-confirmed influenza</measure>
    <time_frame>within a window of 14 days after ILI-onset</time_frame>
    <description>Health Economic Outcome:
To evaluate healthcare utilization and health economic outcomes</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of employment days missed by parent(s)/guardian(s) of subjects with RT-PCR-confirmed influenza</measure>
    <time_frame>within a window of 14 days after ILI-onset</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of days of daycare, school or preschool missed by subjects associated with RT-PCR-confirmed influenza</measure>
    <time_frame>within a window of 14 days after ILI-onset</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10647</enrollment>
  <condition>Influenza Virus</condition>
  <arm_group>
    <arm_group_label>aQIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>flu vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-adjuvanted comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>flu vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</intervention_name>
    <description>1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to &lt;36 months, 0.5 ml: ≥36 months to &lt;72 months</description>
    <arm_group_label>aQIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)</intervention_name>
    <description>1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to &lt;36 months, 0.5 ml: ≥36 months to &lt;72 months</description>
    <arm_group_label>non-adjuvanted comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children, males and females, healthy or at high risk of complications from influenza,
             between ≥6 months to &lt;72 months of age

          -  Documented consent provided by the subject's parent(s)/legal guardian(s)

          -  Subjects and/or subject's parent(s)/legal guardian(s) able to comply with all study
             procedures.

        Exclusion Criteria:

          -  Children with history of allergy to vaccine components.

          -  Additional eligibility criteria may be discussed by contacting the site
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>72 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Program Director</last_name>
    <role>Study Director</role>
    <affiliation>Seqirus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>222, Novartis Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>267, Novartis Investigational Site</name>
      <address>
        <city>Harrisburg</city>
        <state>Arkansas</state>
        <zip>72432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>259, Novartis Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>280, Novartis Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>213, Novartis Investigational Site</name>
      <address>
        <city>Baldwin Park</city>
        <state>California</state>
        <zip>91706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>407, Novartis Investigational Site</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>238, Novartis Investigational Site</name>
      <address>
        <city>La Puente</city>
        <state>California</state>
        <zip>91774</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>411, Novartis Investigational Site</name>
      <address>
        <city>Ontario</city>
        <state>California</state>
        <zip>91762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202, Novartis Investigational Site</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>250, Novartis Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>293, Novartis Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>243, Novartis Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>249, Novartis Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>229, Novartis Investigational Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>416, Novartis Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>287, Novartis Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>412, Novartis Investigational Site</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>224, Novartis Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>417, Novartis Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>404, Novartis Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>285, Novartis Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>277,Novartis Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>234, Novartis Investigational Site</name>
      <address>
        <city>Opa-locka</city>
        <state>Florida</state>
        <zip>33054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>297, Novartis Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>297, Novartis Investigational vaccine</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>410, Novartis Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>401, Novartis iNvestiagtional Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>299, Novartis Investigational Site</name>
      <address>
        <city>DeKalb</city>
        <state>Illinois</state>
        <zip>60115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>268, Novartis Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>209, Novartis Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>210, Novartis Investigational Site</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>274 Novartis Investigational Site</name>
      <address>
        <city>Park City</city>
        <state>Kansas</state>
        <zip>67219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>211, Novartis Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>269, Novartis Investigational Site</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>226, Novartis Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248, Novartis Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>207, Novartis Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>290, Novartis Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>265, Novartis Investigational Site</name>
      <address>
        <city>Haughton</city>
        <state>Louisiana</state>
        <zip>71037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>408, Novartis Investigational Site</name>
      <address>
        <city>Mangham</city>
        <state>Louisiana</state>
        <zip>71259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>225, Novartis Investigational Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>233, Novartis Investigational Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>418, Novartis Investigational SIte</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>262, Novartis Investigational site</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>263, Novartis Investigational Site</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>405, Novartis Investigational Site</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>278, Novartis Investigational Site</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>221, Novartis Investigational Site</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>219, Novartis Investigational Site</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>402, Novartis Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>288, Novartis Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>228, Novartis Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>244, Novartis Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>286, Novartis Investigational site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>255, Novartis Investigational Site</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>414, Novartis Investigational Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>264, Novartis Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>409, Novartis Investigational Site</name>
      <address>
        <city>Boone</city>
        <state>North Carolina</state>
        <zip>28607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>266, Novartis Investigational Site</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>403, Novartis Investigational Site</name>
      <address>
        <city>Clyde</city>
        <state>North Carolina</state>
        <zip>28721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>240, Novartis Investigational Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>254, Novartis iNvestigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>245, Novartis Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>281, Novartis Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>281, Novartis Investigational vaccines</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>256, Novartis Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>292, Novartis Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>270, Novartis Investigational Site</name>
      <address>
        <city>Scottdale</city>
        <state>Pennsylvania</state>
        <zip>15683</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>220, Novartis Investigational Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>406, novartis Investigational Site</name>
      <address>
        <city>Barnwell</city>
        <state>South Carolina</state>
        <zip>29812</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>272, Novartis Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>232, Novartis Investigational Site</name>
      <address>
        <city>Moncks Corner</city>
        <state>South Carolina</state>
        <zip>29461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>291, Novartis Investigational vaccine</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>283, Novartis Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>208, Novartis Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>247, Novartis Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>217, Novartis Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>214, Novartis Investigational Site</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>400, Novartis investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>260, Novartis Investigational Site</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>295, Novartis Investigational Site</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>236, Novartis Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>212, Novartis Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>246, Novartis Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>279, Novartis Investigational Site</name>
      <address>
        <city>Spanish Fork</city>
        <state>Utah</state>
        <zip>84660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>282, Novartis Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>Utah</state>
        <zip>84075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>294, Novartis Investigational Site</name>
      <address>
        <city>West Haven</city>
        <state>Utah</state>
        <zip>84401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>201, Novartis Investigational Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>271, Novartis Investigational Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>251, Novartis Investigational Site</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>296, Novartis Investigational Site</name>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <zip>22180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>180, Novartis Investigational Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>184, Novartis Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>182,Novartis Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>186, Novartis Investigational Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>183, Novartis Investigational Site</name>
      <address>
        <city>Québec</city>
        <zip>G1E 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>001, Novartis Investigational Site</name>
      <address>
        <city>Espoo</city>
        <zip>FI-02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>003, Novartis Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>002, Novartis Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>004, Novartis Investigational Site</name>
      <address>
        <city>Järvenpää</city>
        <zip>FIN-04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>005, Novartis Investigational Site</name>
      <address>
        <city>Kokkola</city>
        <zip>FI-67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>006, Novartis Investigational Site</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>007, Novartis Investigational Site</name>
      <address>
        <city>Pori</city>
        <zip>FI-28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>008, Novartis Investigational Site</name>
      <address>
        <city>Seinäjoki</city>
        <zip>FI-60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>009, Novartis Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>FIN-33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>010, Novartis Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>FIN-20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>011, Novartis Investigational Site</name>
      <address>
        <city>Vantaa</city>
        <zip>FIN-01300</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>030, Novartis Investigational Site</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>023, Novartis Investigational Site</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>020, Novartis Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>026, Novartis Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>025, Novartis Investigational Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>021, Novartis Investigational Site</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>022, Novartis Investigational Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>024, Novartis Investigational Site</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>028, Novartis Investigational Site</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>173, Novartis Investigational Site</name>
      <address>
        <city>Morelia</city>
        <state>Michoacan</state>
        <zip>58070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>176, Novartis Investigational Site</name>
      <address>
        <city>Durango</city>
        <zip>34000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>170, Novartis Investigational Site</name>
      <address>
        <city>Mexico</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>177, Novartis Investigational Site</name>
      <address>
        <city>Mexico</city>
        <zip>06760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>178, Novartis Investigational Site</name>
      <address>
        <city>Mexico</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>175, Novartis Investigational Site</name>
      <address>
        <city>Mexico</city>
        <zip>7020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>300, Novartis Investigational Site</name>
      <address>
        <city>Dasmariñas</city>
        <state>Cavite</state>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>306, Novartis Investigational Site</name>
      <address>
        <city>Alabang</city>
        <state>Muntilupa</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>302, Novartis Investigational Site</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>301, Novartis Investigational Site</name>
      <address>
        <city>Manila</city>
        <zip>1001</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>303, Novartis Investigational Site</name>
      <address>
        <city>Muntinlupa</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>304, Novartis Investigational Site</name>
      <address>
        <city>Muntinlupa</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>305, Novartis Investigational Site</name>
      <address>
        <city>Muntinlupa</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>040, Novartis Investigational Site</name>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>042, Novartis Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-018</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>052, Novartis Investigational Site</name>
      <address>
        <city>Leczna</city>
        <zip>21-010</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>048, Novartis Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>91347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>049, Novartis Investigational Site</name>
      <address>
        <city>Lubartow</city>
        <zip>21-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>051, Novartis Investigational Site</name>
      <address>
        <city>Oborniki Slaskie</city>
        <zip>55-120</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>046, Novartis Investigational Site</name>
      <address>
        <city>Osielsko</city>
        <zip>86-031</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>043, Novartis Investigational Site</name>
      <address>
        <city>Siemianowice Slaskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>047, Novartis Investigational Site</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>041, Novartis Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01809</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>050, Novartis Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>045, Novartis Investigational Site</name>
      <address>
        <city>Wola</city>
        <zip>43-225</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>044, Novartis Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>51215</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>257, Novartis Investigational Site</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>415, Novartis Investigational vaccine</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>415, Novartis Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>80, Novartis Investigational Site</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>075, Novartis Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Galicia</state>
        <zip>15701</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>074, Novartis Investigational Site</name>
      <address>
        <city>Granada</city>
        <zip>18009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>076, Novartis Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>077, Novartis Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>79, Novartis Investigational Site</name>
      <address>
        <city>Malaga</city>
        <zip>29011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>078, Novartis Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>343, Novartis Investigational Site</name>
      <address>
        <city>Banciao</city>
        <state>New Taipei City</state>
        <zip>220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>346, Novartis Investigational Site</name>
      <address>
        <city>Datong</city>
        <state>Taipei City</state>
        <zip>10341</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>344, Novartis Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>345, Novartis Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>340, Novartis Investigational Site</name>
      <address>
        <city>Taipei City</city>
        <zip>10041</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>341, Novartis Investigational Site</name>
      <address>
        <city>Taipei City</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>342, Novartis Investigational Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>321, Novartis Investigational Site</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>322, Novartis Investigational Site</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>323, Novartis Investigational Site</name>
      <address>
        <city>Pathum Wan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>327, Novartis Investigational Site</name>
      <address>
        <city>Ratchathewi</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>325, Novartis Investigational Site</name>
      <address>
        <city>Pathum Thani</city>
        <state>Prathumthani</state>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>326, Novartis Investigational Site</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkhia</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>320, Novartis Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>324, Novartis Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2013</study_first_submitted>
  <study_first_submitted_qc>October 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2013</study_first_posted>
  <disposition_first_submitted>October 14, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>October 14, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 18, 2016</disposition_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

